Omeros Corporation (Nasdaq:OMER) reported that it has identified compounds that interact selectively with each of four additional orphan G protein-coupled receptors (GPCRs) - GPR15, GPR39, GPR78 and GPR161. Omeros has now announced that it has unlocked 14 of the 80 Class A orphan GPCRs. GPCRs represent the premier family of drug targets, with more than 30 percent of currently marketed drugs targeting only 46 GPCRs.
Read the full article and the disclaimer at:http://bestotc.com/18311/stock-alerts/omer-clno-amac-imrs-stocks-report-by-bestotccom/
(OMER, CLNO, AMAC, IMRS) Stocks Report by BestOtc.com
September 21st, 2011 at 09:14 am